Rasi Bhadramani/iStock by way of Getty Pictures
Sagimet Biosciences Inc. (NASDAQ:SGMT) simply reported constructive outcomes from its section 2b examine utilizing denifanstat for the remedy of sufferers with F2-F3 non-alcoholic steatohepatitis [NASH]. It was in a position to meet each main endpoints of this explicit examine, together with a number of secondary endpoints as properly. All of those have been achieved utilizing the drug denifanstat with statistical significance. Having mentioned that, this units up main catalysts as a part of this program. It’s anticipated that the corporate will meet with the FDA in an end-of-phase 2 assembly in 2024. Ought to the assembly go properly, then it’s anticipated that it is going to be in a position to provoke a section 3 examine utilizing denifanstat to deal with NASH sufferers by the 2nd half of 2024. This isn’t the one catalyst to stay up for although. There’s one other catalyst which is anticipated to be launched early on, which if constructive may additionally act as one other alternative to regulate. Particularly, in mild of the current launch of constructive outcomes from the section 2b FASCINATE-2 examine with denifanstat. Sagimet intends to launch security and pharmacokinetic knowledge from a section 1 examine, utilizing denifanstat in sufferers with impaired hepatic operate [impaired liver function] in Q1 of 2024. Such knowledge may very well be launched any day now and will additional entrench that this drug is good in having the ability to deal with sufferers with metabolic problems.
Denifanstat Information For NASH Leads To Different Catalysts
As I famous above, Sagimet Biosciences was in a position to obtain the first endpoints and a number of secondary endpoints from its section 2b examine, generally known as FASCINATE. Such endpoints have been met on this mid-stage examine concentrating on sufferers with F2-F3 non-alcoholic steatohepatitis [NASH] with its drug denifanstat. A complete of 168 biopsy-confirmed NASH sufferers have been randomized 2:1 to obtain both 50 mg denifanstat or a placebo taken as soon as day by day. These sufferers have been handled over a 52-week interval and have been then analyzed for the first and secondary endpoints of the examine. These two main endpoints have been as follows:
- NASH decision with out worsening of fibrosis with ≥2-point discount in NAS.
- ≥ 2-point lower in NAS with out worsening of fibrosis.
With respect to the NASH decision with no worsening of fibrosis endpoint, this main endpoint was met with statistical significance with a p-value of p = 0.002. That’s, 36% of sufferers achieved this endpoint when given 50 mg of denifanstat in comparison with solely 13% of sufferers given placebo. When it comes to the opposite main endpoint of NAS with out worsening of fibrosis, 52% of denifanstat-treated sufferers achieved this, in comparison with solely 20% of sufferers who had acquired a placebo. In my view, this knowledge signifies two gadgets of significance. The primary is that this drug growth program, advancing denifanstat shouldn’t be a “me too” method. In essence, it’s a novel method, whereby it’s extremely differentiated in its mechanism of motion. The second merchandise of significance is the flexibility of the drug itself to successfully goal a number of elements of NASH illness pathology. As a result of it goes after the FASN pathway, it may possibly impact having the ability to assist deal with, similar to:
- Steatosis – elimination of physique fats from the liver.
- Irritation – capacity to assist cut back irritation of the liver.
- Fibrosis – by concentrating on the overactivation of lipid fats synthesis, there may be a capability to scale back fatty acid palmitate – in flip, decreasing longer chain, polyunsaturated fatty acids wanted by an individual’s physique for power.
Some polyunsaturated fatty acids are proper for power manufacturing, however overabundance results in issues within the liver. The concentrating on of the FASH pathway is such a novel style that targets all these mechanisms highlighted immediately above. It’s a very massive market alternative, in that the worldwide non-alcoholic steatohepatitis market is anticipated to achieve $20 billion by 2029. The very last thing to notice is that these have been sufferers with moderate-to-severe fibrosis. That’s, the sufferers recruited into this section 2b FASCINATE examine have been these with Stage F2 or F3 Fibrosis with a NAS ≥4. Despite the fact that the inventory worth is buying and selling increased by 117% to $14.85 per share as of this writing, there are nonetheless loads of alternatives left in 2024 for the inventory to presumably commerce increased. The primary of such catalysts may very well be a extremely profitable end-of-phase 2 assembly with the FDA which is anticipated to occur later in 2024. From there, a second catalyst may very well be the initiation of a section 3 examine utilizing denifanstat for the remedy of NASH sufferers with associated fibrosis.
As I famous to start with the constructive knowledge does result in one other attainable avenue of exploration. Sagimet expects to launch outcomes from one other section 1 examine in Q1 2024 [early 2024 any day now]. This might be with respect to security and pharmacokinetic knowledge from an ongoing section 1 examine treating sufferers with impaired hepatic operate. Being that the corporate did so properly with its drug denifanstat for the remedy of sufferers with F2-F3 NASH, I consider it must also do pretty properly utilizing it to deal with this different impaired liver operate affected person inhabitants.
Further Growth Alternatives With FASN Pathway Inhibition
Despite the fact that the concentrating on of the FASN pathway is good in having the ability to deal with metabolic problems, this exact same pathway is also used to focus on different indications like most cancers and dermatological problems. Each such growth alternatives for this drug are being explored by a associate in China, generally known as Ascletis. In September of 2023, it was in a position to obtain enrollment completion of a section 3 examine treating sufferers with recurrent glioblastoma [GBM]. Its associate now anticipates that this affected person inhabitants will probably be sufficient to permit for a deliberate interim evaluation with respect to progression-free survival. This section 3 examine is utilizing denifanstat together with bevacizumab for the remedy of this affected person inhabitants. A second attainable growth with the exact same associate can be with respect to the discharge of section 2 topline outcomes. That’s, it was proven that denifanstat was in a position to obtain constructive leads to treating sufferers with zits. Plus, the drug was additionally protected/tolerable for sufferers to take. Once more, the logic to additionally goal zits and a few forms of most cancers is as a result of the FASN pathway doesn’t operate correctly with respect to them both. As well as, such development was completed due to what was noticed in preclinical testing. As an illustration, in preclinical fashions, it was proven that FASN inhibitors have been in a position to obtain anti-tumor exercise. How so? That’s, it was proven that tumor cells are literally depending on FASN translation for his or her survival. This was noticed in tumor fashions similar to non-small cell lung most cancers [NSCLC], metastatic-resistant prostate cancers, and hepatocellular carcinomas [liver cancer].
Financials
In accordance with the 10-Q SEC Submitting, Sagimet Biosciences had $101.8 million as of September thirtieth, 2023. A giant purpose for this money available was due to the completion of an upsized IPO it had achieved. It raised a complete of $96.4 million with this upsized providing. It believes that the money available of $101.8 million will probably be sufficient to fund its operations for at the least the following 12 months. Nevertheless, with such restricted money runaway, it selected to boost more money to fund its operations. It did so by way of an announcement of an underwritten public providing of 9 million shares of Collection A typical inventory. As well as, it additionally intends to grant the underwriters as much as a further 1,350,000 shares of its Collection A typical inventory as properly. With this new providing enacted, it ought to have loads of money runway past the unique projection of 12 months.
Dangers To Enterprise
There are a number of dangers that buyers ought to concentrate on earlier than investing in Sagimet Biosciences. The primary threat to contemplate can be with respect to denifanstat which had simply accomplished the section 2b FASCINATE examine treating sufferers with F2 to F3 NASH fibrosis. There is no such thing as a assurance that the end-of-phase 2 assembly to be held in 2024 will grow to be constructive. That’s, the FDA could or could not permit for a section 3 examine to be initiated utilizing this FASN inhibitor drug treating this affected person inhabitants. A second threat to then take into account can be with respect to the usage of this drug concentrating on impaired liver operate sufferers. There is no such thing as a assurance that the protection/pharmacokinetic knowledge to be launched from this trial any day now in Q1 of 2024 will grow to be constructive. A 3rd threat to make notice of can be with respect to the 2 ongoing growth alternatives I famous above, with licensed denifenstat being utilized in China to deal with sufferers with zits and recurrent Glioblastoma [GBM].
A deliberate interim evaluation is anticipated quickly for the recurrent GBM affected person inhabitants and there’s no assure that the endpoint of progression-free survival [PFS] will probably be met. Regardless of robust knowledge from a section 2 examine utilizing denifenstat for the remedy of sufferers with zits, there isn’t any approach of figuring out whether or not or not this program will reach additional growth in different medical research. A fourth threat to then take into account can be with respect to the FASN pathway itself. Despite the fact that the inhibition of the FASN pathway has been stable in NASH sufferers [with primary endpoints and multiple secondary endpoints being met], there isn’t any assurance that the drug will be capable to obtain comparable or superior knowledge in the direction of these different indications.
Conclusion
Sagimet Biosciences has been in a position to obtain the first endpoints and a number of secondary endpoints from the section 2b FASCINATE examine, which used denifanstat for the remedy of sufferers with F2-F3 NASH. Because of this it’s now on deck to satisfy with the FDA and see if it is going to be in a position to provoke a section 3 examine for this explicit program. I consider the promise on this biotech is that the FASN pathway is not only solely able to being utilized to solely goal metabolic problems. It will also be used to focus on sure dermatological problems similar to zits after which sure forms of cancers like recurrent Glioblastoma. Hopefully, its associate Ascletis can proceed these packages to completion. Not solely as a result of that might enhance the inventory worth for shareholders, which it may, but additionally the truth that it could add extra goal indications as properly. For instance, it has plans to file an IND submitting to the FDA to start medical testing of TVB-3567 for the remedy of sufferers with zits. A number of growth alternatives like this might function extra pictures on aim for the pipeline.
